<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467127</url>
  </required_header>
  <id_info>
    <org_study_id>Headache 2015</org_study_id>
    <nct_id>NCT02467127</nct_id>
  </id_info>
  <brief_title>Vitamin D Plasma Level and Its Role in Headache</brief_title>
  <acronym>VITDHEAD</acronym>
  <official_title>The Role of Vitamin D Plasma Levels in the Development of Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cantanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cantanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date there are conflicting data concerning a correlation between plasma vitamin D levels
      and headache.

      The aim of this study was to evaluate plasma vitamin D levels in patients with headache
      admitted to the Center of Headache of Pugliese Ciaccio Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several papers suggest that inflammation is able to induces both headache and low levels of
      vitamin D. However, to date a correlation between plasma vitamin D levels and headache has
      not been demonstrated. Recently we documented that low levels of Vitamin D are related to a
      low statin efficacy. In this study we will evaluate the plasma levels of vitamin D in
      patients with headache admitted to the Center of Headache of Pugliese Ciaccio Hospital.

      Moreover it will be also evaluated:

        -  the correlation between efficacy and safety of drugs used in headache treatment and
           plasma vitamin D levels.

        -  the role of vitamin D supplementation on both headache symptoms and drug effects.

      Plasma vitamin D levels in patients with headache will be evaluated respect to patients
      without headache.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of vitamin D using high performance liquid chromatography</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache pain through the Visual Analog Scale (VAS)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without headache. No drugs will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Headache</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with headache &gt; 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic headache with drug overuse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with headache &gt; 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Headache</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without chronic headache but with an history of headache &lt; 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D supplementation</intervention_name>
    <description>In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.</description>
    <arm_group_label>Chronic Headache</arm_group_label>
    <arm_group_label>Chronic headache with drug overuse</arm_group_label>
    <arm_group_label>Acute Headache</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute or chronic headache diagnosed according to the clinical and radiological
             criteria of the headache Association

        Exclusion Criteria:

          -  allergy to drugs,

          -  progressive serious medical conditions (such as cancer, AIDS or end-stage renal
             disease)

          -  renal diseases (serum creatinine concentration more than 1.2 times the upper limit of
             the normal range according to the central laboratory definition reference values)

          -  liver dysfunction (serum alanine or aspartate transaminase concentrations more than
             1.5 times the upper limit of normal range according to the central laboratory
             definition reference values)

          -  alcohol consumption (&gt;3 alcoholic beverages daily)

          -  substance abuse

          -  inability to give written informed consent

          -  actual or recent (3-month) treatment with corticosteroids, indomethacin or other
             antinflammatory drugs.

          -  secondary headache
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gallelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catanzaro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pugliese Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cantanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

